Journal
MINI-REVIEWS IN MEDICINAL CHEMISTRY
Volume 11, Issue 2, Pages 114-124Publisher
BENTHAM SCIENCE PUBL LTD
DOI: 10.2174/138955711794519528
Keywords
Small interfering RNA; pharmacodynamics; cancer; oncogene; apoptosis; cell cycle; angiogenesis; multidrug resistance
Categories
Funding
- NSFC [20831003, 90813001, 20833006, 90913007, 20903086]
- 973 Project [2011CB93 6004]
- Chinese Academy of Sciences
Ask authors/readers for more resources
Small interfering RNA (siRNA) has become a specific and powerful tool to turn off the expression of target genes, and has turned into a promising tool in molecular medicine. It can be targeted against cancer by several strategies. These include the suppression of overexpressed oncogenes, retarding cell division by interfering with cyclins and related genes or enhancing apoptosis by inhibiting anti-apoptotic genes. RNA interference (RNAi) against multidrug resistance (MDR) genes or chemo/radio-resistance and angiogenesis targets may also provide beneficial cancer treatments. Successful cancer therapy by siRNA in vitro and in vivo provides the enthusiasm for potential therapeutic applications of this technique. Here, we review RNAi in cancer therapy, highlighting recent progress and examining the hurdles that must be overcome before this promising technology is ready for clinical use.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available